Eagle Asset Management Inc. Sells 34,215 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Eagle Asset Management Inc. lowered its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 18.1% in the third quarter, HoldingsChannel reports. The fund owned 154,652 shares of the biotechnology company’s stock after selling 34,215 shares during the period. Eagle Asset Management Inc.’s holdings in Blueprint Medicines were worth $15,594,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in BPMC. Charles Schwab Investment Management Inc. grew its position in shares of Blueprint Medicines by 9.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 597,232 shares of the biotechnology company’s stock worth $55,244,000 after buying an additional 50,736 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Blueprint Medicines by 48.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company’s stock valued at $23,332,000 after purchasing an additional 82,693 shares during the period. Intech Investment Management LLC acquired a new position in Blueprint Medicines during the 3rd quarter worth approximately $1,712,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new position in Blueprint Medicines in the third quarter valued at $6,465,000. Finally, Advisors Asset Management Inc. grew its holdings in shares of Blueprint Medicines by 17.6% in the 3rd quarter. Advisors Asset Management Inc. now owns 5,054 shares of the biotechnology company’s stock valued at $467,000 after acquiring an additional 756 shares in the last quarter.

Blueprint Medicines Stock Down 2.6 %

Shares of NASDAQ BPMC opened at $94.15 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. The firm’s 50 day simple moving average is $90.36 and its two-hundred day simple moving average is $98.53. The stock has a market capitalization of $5.98 billion, a P/E ratio of -44.62 and a beta of 0.59. Blueprint Medicines Co. has a one year low of $66.61 and a one year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.08. The firm had revenue of $128.20 million during the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The business’s revenue was up 126.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.20) EPS. As a group, analysts expect that Blueprint Medicines Co. will post -3.68 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Wedbush reaffirmed an “outperform” rating and issued a $135.00 target price on shares of Blueprint Medicines in a report on Thursday, November 14th. Baird R W raised shares of Blueprint Medicines to a “strong-buy” rating in a research report on Friday, August 2nd. StockNews.com raised Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, November 8th. HC Wainwright reaffirmed a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a report on Friday, November 15th. Finally, Needham & Company LLC restated a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, November 15th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Blueprint Medicines presently has an average rating of “Moderate Buy” and a consensus target price of $122.11.

Insider Activity

In other Blueprint Medicines news, insider Fouad Namouni sold 3,633 shares of the stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total value of $324,499.56. Following the transaction, the insider now directly owns 69,070 shares in the company, valued at approximately $6,169,332.40. This trade represents a 5.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.21% of the company’s stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.